AI Article Synopsis
- The study examined how different histological variants of upper tract urothelial carcinoma affect outcomes after radical nephroureterectomy in 1,648 patients.
- About 24.2% of patients showed variant histologies, particularly squamous cell and glandular types, which were linked to more aggressive tumor characteristics.
- Although variant histology correlated with higher disease recurrence and cancer-specific mortality in initial analyses, this association was not significant when adjusting for other clinical factors.
Article Abstract
Purpose: We investigated the clinical and prognostic impact of variant histologies on upper tract urothelial carcinoma outcomes after radical nephroureterectomy.
Materials And Methods: Data on 1,648 patients with upper tract urothelial carcinoma treated with radical nephroureterectomy without preoperative chemotherapy or radiotherapy were reviewed for histological differentiation and variants. We analyzed differences between pure upper tract urothelial carcinoma and upper tract urothelial carcinoma with variant histology, and differences in the histological variants using different stratifications.
Results: A total of 398 patients (24.2%) had histological upper tract urothelial carcinoma variants. The most common variants were squamous cell and glandular differentiation in 9.9% and 4.4% of cases, respectively. Histological variants were associated with advanced tumor stage, tumor multifocality, sessile tumor architecture, tumor necrosis, lymphovascular invasion and lymph node metastasis compared to pure upper tract urothelial carcinoma (p ≤0.031). On univariable analysis variant histology was associated with disease recurrence (p = 0.002) and cancer specific mortality (p = 0.003). In 174 patients treated with adjuvant chemotherapy there was no difference in disease recurrence or survival between variant histology and pure upper tract urothelial carcinoma (p = 0.42 and 0.59, respectively). On multivariable analysis adjusted for the effects of standard clinicopathological characteristics variant histology was not associated with either end point.
Conclusions: Almost 25% of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy harbored histological variants. Variant histology was associated with features of biologically aggressive upper tract urothelial carcinoma. While variant histology is associated with worse outcomes on univariable analysis but this effect did not remain significant on multivariable analysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.juro.2012.04.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Using apparent diffusion coefficient maps and radiomics to predict pathological grade in upper urinary tract urothelial carcinoma.
BMC Med Imaging
December 2024
Department of Radiology, Peking University First Hospital, 8, Xishiku Street, Xicheng District, Beijing, 100034, China.
Background: The apparent diffusion coefficient (ADC) has been reported as a quantitative biomarker for assessing the aggressiveness of upper urinary tract urothelial carcinoma (UTUC), but it has typically been used only with mean ADC values. This study aims to develop a radiomics model using ADC maps to differentiate UTUC grades by incorporating texture features and to compare its performance with that of mean ADC values.
Methods: A total of 215 patients with histopathologically confirmed UTUC were enrolled retrospectively and divided into training and test sets.
Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Cancer: An Updated Meta-Analysis of Randomized Controlled Trials.
Clin Genitourin Cancer
December 2024
Clion Clínica de Oncologia, Salvador, Bahia, Brazil.
Introduction: Neoadjuvant cisplatin-based chemotherapy followed by radical surgery is the standard treatment for muscle-invasive urothelial carcinoma (MIUC). The Checkmate-274 and AMBASSADOR trials have demonstrated improvements in disease-free survival (DFS) with adjuvant immunotherapy. Consequently, this meta-analysis aimed to assess the effectiveness of strategies involving checkpoint inhibitors in managing high-risk MIUC.
View Article and Find Full Text PDFCutaneous Metastasis of Bladder Cancer: A Systematic Review.
Cureus
November 2024
Department of Obstetrics and Gynecology, Beaumont Hospital, Dearborn, USA.
Bladder cancer is one of the main causes of urogenital cancer (30-35% of the total urological cancers). Although metastases from urologic tumors are rare, it is associated with a high mortality rate. The location and pattern of metastasis are random and unpredictable.
View Article and Find Full Text PDFSingle-Cell RNA Sequencing Reveals the Tumor Heterogeneity and Immunosuppressive Microenvironment in Urothelial Carcinoma.
Cancer Sci
December 2024
Cixi Institute of Biomedical Engineering, Chinese Academy of Science (CAS), Ningbo Institute of Materials Technology and Engineering, CAS Ningbo, Ningbo, China.
Urothelial carcinoma (UC) can arise from either the lower urinary tract or the upper tract; they represent different disease entities and require different clinical treatment strategies. A full understanding of the cellular characteristics in UC may guide the development of novel therapies. Here, we performed single-cell transcriptome analysis from four patients with UC of the bladder (UCB), five patients with UC of the ureter (UCU), and four patients with UC of the renal pelvis (UCRP) to develop a comprehensive cell atlas of UC.
View Article and Find Full Text PDFLetter: Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel.
J Urol
December 2024
Department of Urology, NYU Grossman School of Medicine, New York, New York.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!